Orforglipron (Foundayo): How the GLP-1 Pill Works, Costs, and Compares

Orforglipron (brand name Foundayo, pronounced or-for-GLIP-ron) is a once-daily oral GLP-1 weight-loss pill from Eli Lilly, approved by the FDA on April 1, 2026 for adults with obesity, or overweight with weight-related medical problems, when used with a reduced-calorie diet and more physical activity ^[1][6]. In its main Phase 3 trial, people taking the highest dose lost an average of 12.4% of body weight (27.3 lbs) over 72 weeks, compared with 0.9% (2.2 lbs) for placebo ^[1][2]. Self-pay prices run roughly $149 to $349 per month depending on dose, while eligible people with commercial insurance may pay as little as $25 per month and eligible Medicare Part D beneficiaries $50 per 28- or 30-day supply ^[1][6].

Unlike injected GLP-1s such as Wegovy and Zepbound, and unlike the oral Wegovy pill, Foundayo is a small molecule rather than a peptide, and it can be taken any time of day with no restrictions on food or water ^[1][2][4]. It is Lilly’s second FDA-approved obesity medicine, and it became available through LillyDirect with prescriptions accepted immediately and shipping beginning April 6, 2026, followed by broader retail and telehealth availability ^[1].

What is orforglipron and who makes it?

Orforglipron is the active ingredient in Foundayo (fown-DAY-oh), a once-daily oral tablet made by Eli Lilly ^[1][6]. The FDA approved it on April 1, 2026 for adults with obesity, or overweight plus at least one weight-related medical problem, to lose excess weight and keep it off alongside a reduced-calorie diet and increased physical activity ^[1][6].

The molecule was discovered by Chugai Pharmaceutical and licensed by Lilly in 2018 ^[1][2]. The approval came through the FDA commissioner’s voucher program, which grants speedy reviews to drugs aligned with national health priorities ^[4]. Lilly has submitted orforglipron for weight management and/or type 2 diabetes in more than 40 countries and plans to launch in each shortly after approval ^[1].

How is a small-molecule GLP-1 pill different from injections and the Wegovy pill?

Orforglipron is a small molecule, non-peptide GLP-1 receptor agonist ^[1][2][4]. In practice, it can be taken any time of day with no restrictions on food or water intake ^[1][2].

The Wegovy pill (oral semaglutide), which the FDA approved in December 2025 and Novo Nordisk manufactures, is an oral peptide that is harder for the body to absorb, so it must be taken in the morning at least 30 minutes before any food or drink other than water ^[4]. Lilly’s own claim is that Foundayo is the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions ^[1].

Small molecules are metabolized in the liver, which is why researchers generally watch for liver-damage signals with this type of drug; no hepatic safety signal was observed in the ATTAIN-1 trial ^[2][4]. Because small molecules differ chemically from peptide injectables, differences in manufacturing and market competition could affect pricing over time ^[6].

The tablet is swallowed whole — it should not be broken, crushed, or chewed — and only one tablet is taken per day ^[6].

How much weight did people lose in the ATTAIN-1 trial?

In ATTAIN-1 (NCT05869903), a Phase 3, 72-week, randomized, double-blind, placebo-controlled trial, 3,127 adults with obesity or overweight plus at least one comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease) and no diabetes were assigned to orforglipron or placebo ^[1][2]. Results were presented at the EASD 2025 annual meeting and published in the New England Journal of Medicine, announced September 16, 2025 ^[2].

The trial studied capsule doses of 6 mg, 12 mg, and 36 mg, and all three beat placebo on the primary endpoint at 72 weeks ^[2]. The approved tablet doses go up to 17.2 mg, which Lilly stated are equivalent to the trial capsule doses ^[4].

At the highest dose, the results depend on how they are measured — both figures come from the same trial:

• Efficacy estimand: -12.4% (-12.4 kg; -27.3 lbs) versus -0.9% (-2.2 lbs) for placebo. This estimand represents the result had all randomized participants stayed on the study drug for 72 weeks without prohibited weight treatments ^[1][2].
• Treatment-regimen estimand: -11.2% (-25.0 lbs) per the NEJM-published figures ^[2]. Lilly’s approval release states 11.1% (25 lbs) versus 2.1% (5.3 lbs) for placebo, describing participants’ results regardless of trial completion ^[1].

Participants had a mean baseline weight of 103.2 kg (227.5 lbs) and BMI of 37.0 ^[2]. At the highest dose (efficacy estimand), 77.1% lost at least 5% of body weight, 59.6% lost at least 10%, 39.6% lost at least 15%, and 20.1% lost at least 20%, versus 22.1%, 8.6%, 3.6%, and 1.6% on placebo ^[2].

The highest dose also reduced waist circumference by 11.1 cm (4.4 in) versus 2.1 cm (0.8 in) for placebo, and improved several cardiovascular risk markers: non-HDL cholesterol -8.5%, triglycerides -21.6%, and systolic blood pressure -6.7 mm Hg ^[2]. In a pre-specified exploratory analysis, the highest dose reduced hsCRP (an inflammation marker) by 47.7% ^[2]. Among the 1,127 participants who started the trial with prediabetes, up to 91% of those on orforglipron reached near-normal blood sugar levels versus 42% on placebo ^[2].

A consumer source cites average weight loss by approved tablet dose as 7.4% (about 17 lbs) at 5.5 mg, 8.3% (about 19 lbs) at 9 mg, and 11.1% (about 25 lbs) at 17.2 mg ^[7].

A second registration trial, ATTAIN-2 (NCT05872620), enrolled more than 1,600 adults with obesity or overweight plus type 2 diabetes over 72 weeks ^[1]. The ATTAIN program enrolled more than 4,500 people across its two registration trials ^[1][2].

How does orforglipron compare with the Wegovy pill and injectable GLP-1s?

These are cross-trial figures, not head-to-head comparisons — the studies ran in different populations for different lengths of time. The Wegovy pill led to 13.6% weight loss in a 64-week Phase 3 trial, while orforglipron showed 11.2% (treatment-regimen estimand) in its 72-week study ^[4].

The two pills also differ in their approved uses. The Wegovy pill is also approved to cut the risk of cardiovascular complications, while Foundayo’s indication is weight management only ^[1][4]. Novo has argued there is more safety evidence for its pill because it contains the same ingredient as the long-marketed injectable Wegovy ^[4].

Daily oral GLP-1s are generally seen as less effective than weekly injectables, but they appeal to people who want no needles, and pills are easier to distribute and do not require cold storage ^[4]. A consumer source cites average body-weight loss over time of about 15% for Wegovy and about 21% for Zepbound (tirzepatide) injections ^[7].

On price, Novo launched the Wegovy pill at a cash price of up to $299 per month, undercutting Lilly’s earlier stated plan of $149 to $399; at approval, Lilly said it will sell its pill at up to $299 per month if patients continually renew the prescription ^[4].

How is Foundayo dosed?

This is the published dosing information from the label and reference sources, not a recommendation for any individual:

Treatment starts at 0.8 mg once daily, increases to 2.5 mg after at least 30 days, then to 5.5 mg after another 30 days, and may then step up every 30 days to 9 mg, 14.5 mg, and 17.2 mg once daily, which is the maximum dose ^[6]. It is taken once daily with or without food, and the tablet is swallowed whole ^[1][6].

The roughly every-4-week titration steps are designed to limit side effects, and monthly cost can rise as the dose rises ^[6][7]. In ATTAIN-1, participants started at 1 mg once daily and stepped up every four weeks to their assigned maintenance dose ^[2].

What does orforglipron cost per month?

Self-pay prices typically run about $149 to $349 per month, depending on dose ^[6]. These are manufacturer and self-pay program figures, not guaranteed list prices — they can change and may require qualifying for the Foundayo Self-Pay Savings Card or Self Pay Journey Program ^[1][6].

Dose	Approximate self-pay price per month
0.8 mg (lowest)	About $149 (30-day supply) [1][6]
2.5 mg	$199 [6]
5.5 mg and 9 mg	Around $299 [6]
14.5 mg and 17.2 mg	Standard $349 applies if the prescription is not refilled within 45 days [6]

Self-pay access is available through LillyDirect with free home delivery and through local pharmacies; Foundayo is also listed on the TrumpRx platform, which routes to LillyDirect ^[1][6]. LillyDirect partner pharmacies include Prescryptive, Amazon Pharmacy, Fuze Health, Gifthealth, and Walmart Pharmacy, and LillyDirect Pharmacy can be reached at 1-844-559-3471 ^[6].

Will commercial insurance or Medicare cover it?

Eligible patients with commercial insurance may pay as little as $25 per month with the Foundayo savings card, though other plans may have higher copays depending on deductibles and formulary tier ^[1][6]. Coverage for weight-management medications varies widely between plans, and some insurers require prior authorization ^[6].

For Medicare: weight-loss drugs are generally excluded from standard Part D coverage under federal law, though GLP-1s are covered when prescribed for certain FDA-approved conditions such as type 2 diabetes, sleep apnea, MASH, or cardiovascular risk reduction ^[6]. The temporary Medicare GLP-1 Bridge program, launched July 1, 2026, lets eligible Part D beneficiaries pay $50 per 28- or 30-day supply ^[1][6].

Bridge program details:

• Covered drugs are the Foundayo tablet, Wegovy injection or tablet, and Zepbound KwikPen; single-dose Zepbound pens and vials are not covered ^[6].
• The $50 payment does not count toward the Part D deductible or annual out-of-pocket limit, and is paid at the pharmacy counter ^[6].
• Eligibility requires Part D enrollment plus Medicare, BMI, and health criteria; a prescriber must confirm the medication is part of a weight-management plan with diet and exercise and complete any prior authorization ^[6].
• Coverage runs through December 31, 2027 ^[6].

Medicaid coverage varies by state ^[6]. Beyond insurance status, actual costs depend on the deductible, copay tier, prior authorization or step therapy rules, dose, pharmacy channel, and location ^[6].

What are the side effects and warnings?

The most common side effects are nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, swollen belly, fatigue, belching, heartburn, gas, and hair loss ^[1][3].

In ATTAIN-1 at the 36 mg dose versus placebo: nausea 33.7% vs 10.4%, constipation 25.4% vs 9.3%, diarrhea 23.1% vs 9.6%, and vomiting 24.0% vs 3.5% ^[2]. Gastrointestinal events were generally mild to moderate, and the overall safety profile was consistent with the GLP-1 class ^[2]. Discontinuation due to adverse events was 5.3% at 6 mg, 7.9% at 12 mg, and 10.3% at 36 mg, versus 2.7% on placebo ^[2].

The label carries a warning that Foundayo may cause thyroid tumors, including thyroid cancer; symptoms to watch for include a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath ^[1][3]. It should not be used by people with a personal or family history of medullary thyroid carcinoma, by people who have Multiple Endocrine Neoplasia syndrome type 2, or by anyone who has had a serious allergic reaction to orforglipron or its ingredients ^[1][3].

Other serious risks listed include pancreatitis, severe stomach problems, dehydration leading to kidney problems, low blood sugar (higher risk when used with insulin or a sulfonylurea), serious allergic reactions, vision changes in people with type 2 diabetes, and gallbladder problems ^[1][3]. Foundayo should not be used with other GLP-1 receptor agonist medicines, and it is not known whether it is safe and effective in children ^[1][3].

What else is orforglipron being studied for?

Beyond chronic weight management, orforglipron is being studied as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease, and stress urinary incontinence ^[1]. A submission for type 2 diabetes was anticipated in 2026 ^[2].

Why did the approval come so fast, and does that matter?

Foundayo was approved through the FDA commissioner’s voucher program, which grants speedy reviews to drugs aligned with national health priorities ^[4]. That program has drawn criticism from agency insiders as a vehicle for political interference ^[4]. Lilly received its voucher as part of a White House deal to lower obesity drug prices in certain settings ^[4].

Reuters reported that Lilly pressed the FDA for a faster answer on whether its application was complete; a Lilly spokesperson said the company expected a fulsome, science-based review ^[4]. Lilly also notes that fewer than 1 in 10 people who could benefit from a GLP-1 are currently taking one ^[1].

What should someone ask a clinician or pharmacist before starting?

Questions worth bringing to a prescriber or pharmacist include confirming coverage, formulary tier, and any prior authorization requirements before starting, since pricing and coverage change over time ^[6]. A personal or family history of medullary thyroid carcinoma, or a personal diagnosis of MEN 2, is a contraindication to raise, and use of insulin or a sulfonylurea raises hypoglycemia risk ^[1][3]. Whether Foundayo is an appropriate option for any individual is a decision to make with a clinician.

Sources

1. Eli Lilly and Company. FDA approves Lilly’s Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. April 1, 2026.
2. Eli Lilly and Company. Lilly’s oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine. September 16, 2025.
3. Eli Lilly and Company. Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. July 23, 2026.
4. STAT. Eli Lilly’s obesity pill approved by FDA, setting up competition with Novo Nordisk. April 1, 2026.
5. AP News. FDA grants speedy approval to Eli Lilly’s weight-loss pill for obesity.
6. Drugs.com. How much does Foundayo cost? July 22, 2026.
7. Noom. Foundayo (orforglipron) cost: With and without insurance in 2026. April 27, 2026.
8. Eli Lilly and Company. Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial. December 18, 2025.
9. Nature Medicine. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.
10. Fierce Pharma. The Oral GLP-1 Tracker: Novo’s Wegovy pill, Lilly’s Foundayo continue prescription climb. September 11, 2026.
11. PR Newswire. FDA approves Novo Nordisk’s Wegovy pill, the first and only oral GLP-1 for weight loss in adults.
12. Medscape. FDA Okays Oral Semaglutide 25 mg for Weight Management. December 23, 2025.
13. AJMC. FDA Approves Lilly’s Oral GLP-1 Orforglipron for Obesity. April 1, 2026.
14. Eli Lilly and Company. Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause. June 7, 2026.
15. Fierce Pharma. Lilly’s obesity pill Foundayo ‘disappointed’ in Q2, as injectables continue to boom. August 5, 2026.
16. Ozmosi. The Obesity Drug Pipeline in 2026: Emerging Targets, Companies and Clinical Readouts. August 17, 2026.
17. Eli Lilly and Company. Foundayo (orforglipron) Coverage & Savings: Self-Pay & Savings Card.
18. NovoCare. Wegovy (semaglutide) Cost, Coverage, & Savings Resources.